NDAORALSOLUTION
Approved
May 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PEDIAPRED (prednisolone sodium phosphate) by Alcon is clinical pharmacology naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. First approved in 1986.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEDIAPRED is an oral glucocorticoid solution containing prednisolone sodium phosphate, a synthetic adrenocortical steroid used primarily for anti-inflammatory and immunosuppressive effects. It is indicated for pediatric patients requiring corticosteroid replacement or treatment of inflammatory and autoimmune conditions. The drug works by inhibiting inflammatory processes, suppressing immune cell production, and modulating glucose and lipid metabolism.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating transition from defense to brand maintenance for supporting teams.
Mechanism of Action
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many…
Worked on PEDIAPRED at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.